Biomedical Excellence for Safer Transfusion
  • Biomedical Excellence for Safer Transfusion (BEST)
    Biomedical Excellence for Safer Transfusion (BEST)

    BEST Collaborative is an international research organization that works collaboratively to explore ways to improve transfusion-related services through…

  • BEST Membership
    BEST Membership

    The BEST collaborative is a unique free-standing group of over 150 manufacturers, clinicians, and scientists from 22 countries committed to improving transfusion…

  • BEST Meetings
    BEST Meetings

    BEST meetings are held twice per year. and attendance is open to all members. Invited guests may attend with pre-approval of the Chair.

  • Press Releases
    Press Releases

    Official notices regarding significant publications, special events and member news.

  • Recommended Procedures
    Recommended Procedures

    Several best practice documents are available for download

  • Sponsorship
    Sponsorship

    Any commercial organization or Blood Service interested in advancing the purpose of BEST may become a supporter of BEST by paying the annual dues amount; providing a…

Latest News

Transfusion Update Event

was held in Sydney Australia in April 2017.

Press Release 20 July 2016

Interference of New Drugs in Compatibility Testing for Blood Transfusion

Press Release 26 February 2014

Michael Murphy, MD Elected Chair, effective October 2014

Member Reminders

  • The La Jolla BEST Book and meeting presentations are available for download in the members area.
  • Make your hotel reservations for the Florence Meeting now! The booking form is available in the members area.

October 2017

La Jolla 2017

BEST LIV Meeting

The meeting dates for the Fall Meeting are October 4-5, 2017.

Location

  • Hilton La Jolla Torrey Pines
  • Immediately prior to the AABB Meeting in San Diego

 

April 2018

Florence

BEST LV Meeting

Dates are confirmed for Florence, Italy for April 27-28, 2018.

Important News

  • A booking form for the Grand Hotel Mediterraneo is posted in the Members area

 

A A A

The Conventional Components Team

The Conventional Components Team of the BEST Collaborative coordinates individual efforts and conducts collaborative international studies that address developmental and regulatory issues regarding the composition and validation of the conventional blood components: red cells, platelets and plasma. Our projects are based principally in the laboratories and blood centers of the BEST members. We perform pilot exploratory studies, inter-laboratory comparisons, and small randomized trials. While principally focused on the methods and needs of advanced blood systems, we have also performed projects suited to countries with emerging economies or even to blood use in field and emergency situations. 

Recent projects from the Conventional Components Team have included:

  • The collaborative development of several new platelet storage solutions.
  • An evaluation of the metabolic effects of holding whole blood at room temperature for up to 26 hours before processing into components
  • A major review of all Cr-51 radioactive red cell recovery studies in the past 15 years to understand the implications of new US FDA standards
  • Development of a flow cytometric method to count platelets
  • Standardization of measurement of platelet activation markers
  • Survey of commercially available blood bags

Current projects include:

  • Comparison and standardization of hemolysis measurement
  • Estimation of the donor effect on various in vitro outcomes
  • Determination of the effect of gamma irradiation on red cell concentrates, and the implication for current guidelines
  • Descriptive survey of current practices of post production processing steps
  • Evaluation of quality control of pathogen reduction technologies
  • Exploration of the field of non-traditional use of blood components

The Conventional Components Team is working to improve the processing, quality, and utility of conventional blood components.

The team leaders for Conventional Components are Dana Devine, PhD, Chief Medical & Scientific Officer at Canadian Blood Services, Professor of Pathology and Laboratory Medicine at the University of British Columbia and Pieter van der Meer, PhD, Senior Scientist, Sanquin Blood Bank, Amsterdam, the Netherlands.